JanOne Inc. Develops Plan for Treating Methamphetamine Use Disorder
January 4, 2022
JanOne Inc. has Started Working on Developing New Treatments for Treating the ~1.5 Million Americans who Abuse Methamphetamines LAS VEGAS, Jan. 4, 2022 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a company that focuses on the development of drugs with non-addictive, pain-relieving properties - in an effort to further reduce the drug addiction epidemic - previously... READ MORE
October 27, 2021
Minneapolis – October 27, 2021 – ARCA Recycling, Inc., a wholly owned subsidiary of JanOne Inc. (NASDAQ: JAN), launched two new appliance recycling programs in Northern California, with a focus on decreasing the release of greenhouse gas (GHG) and ozone-depleting emissions into the atmosphere. The primary goal of these programs is to prevent the release... READ MORE
October 19, 2021
MINNEAPOLIS, Oct. 19, 2021 /PRNewswire/ -- ARCA Recycling, Inc., a wholly owned subsidiary of JanOne Inc. (NASDAQ: JAN), has seen major growth in its appliance replacement programs throughout the past 12 months, with the addition of new contracts signed this year that total more than $3 million. It is estimated that these new contracts could... READ MORE
October 12, 2021
Minneapolis – October 12, 2021 – ARCA Recycling, Inc., a wholly owned subsidiary of JanOne Inc. (NASDAQ: JAN), recently opened a new recycling facility in Grand Rapids, Michigan to support its growth in the state. ARCA was recently awarded multiple contracts to provide appliance recycling services for major Michigan electric utilities through the end of... READ MORE
September 28, 2021
JanOne’s management is encouraged regarding Recent Discussions on Potential Phase 2b Trial Endpoints and Possible Regulatory Routes for JAN101 as Treatment for Peripheral Artery Disease (PAD) LAS VEGAS, [DATE], 2021 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a company that focuses on the development of treatments for conditions that cause severe pain – in conjunction with... READ MORE
July 22, 2021
CPC to Manage Planning, Organization, and Day-to-Day Execution of the Trial LAS VEGAS, July 22, 2021 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced that it has selected CPC Clinical Research (CPC), a full-service academic research organization... READ MORE
June 23, 2021
Company Fully Prepared to Commence Phase 2b Trials of JAN101 for Peripheral Artery Disease (PAD) as Soon as New Protocol is Approved by the FDA LAS VEGAS, June 23, 2021 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today... READ MORE
June 22, 2021
Global Contract Research Organization (CRO) Avania to Manage All Regulatory Affairs in Connection with JanOne's Phase 2b Trial Preparedness and Execution LAS VEGAS, June 22, 2021 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced its selection of... READ MORE
June 15, 2021
World leader in addiction science joins team of experts in diseases and disorders that cause chronic pain LAS VEGAS, June 15, 2021 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced the appointment of Nicholas E. Goeders, Ph.D.... READ MORE